(Photo Illustration by Cheng Xin/Getty Images)Getty ImagesDeal OverviewOn May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business into a standalone entity (New Diabetes Company). This strategic move is designed to streamline Medtronic’s portfolio, sharpen its focus on high-margin growth areas, and unlock shareholder value.Post spin-off, Medtronic (RemainCo) will continue to operate a ...